Provided by Tiger Trade Technology Pte. Ltd.

Camp4 Therapeutics Corp.

3.84
-0.2000-4.95%
Post-market: 3.900.0600+1.56%19:30 EDT
Volume:994.72K
Turnover:3.87M
Market Cap:240.97M
PE:-1.73
High:4.15
Open:3.99
Low:3.76
Close:4.04
52wk High:7.75
52wk Low:2.85
Shares:62.75M
Float Shares:50.71M
Volume Ratio:4.66
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2250
EPS(LYR):-2.6500
ROE:-545.85%
ROA:-45.25%
PB:-347.72
PE(LYR):-1.45

Loading ...

Piper Sandler Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)

TIPRANKS
·
Sep 29

CAMP4 Details ASCEND Trial Plans in SYNGAP1 Disorder

TIPRANKS
·
Sep 29

Camp4 Therapeutics Corp - to Initiate Cmp-002 Clinical Trial in Q4 2026

THOMSON REUTERS
·
Sep 10

Camp4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of Cmp-002 in Patients with Syngap1-Related Disorder

THOMSON REUTERS
·
Sep 10

Camp4 Therapeutics CFO Kelly Gold Reports Spouse Purchase of 10,000 Shares Worth $39,600

Reuters
·
Sep 03

Major Insider Move at CAMP4 Therapeutics Raises Investor Eyebrows

TIPRANKS
·
Sep 01

Canadian GoldCamps Secures 85% Stake in Stealthwall West Gold Project

TIPRANKS
·
Sep 01

Camp4 Therapeutics Director Andrew J. Schwab Reports Disposal of 400,000 Common Shares Valued at $1.62 Million

Reuters
·
Sep 01

Camp4 Therapeutics Director Andrew J. Schwab Disposes of 10 Shares Worth $45

Reuters
·
Aug 27

Major Insider Move at CAMP4 Therapeutics Shakes Up Investor Buzz

TIPRANKS
·
Aug 22

Camp4 Therapeutics Director Andrew J. Schwab Disposes of USD 879,374 in Common Shares

Reuters
·
Aug 22

Canadian GoldCamps Clears Key Regulatory Hurdle With NI 43-101 Report for Mercator Project

TIPRANKS
·
Aug 22

Camp4 Therapeutics CSO Daniel Tardiff Disposes of 1,738 Common Shares Worth $8,272.88

Reuters
·
Aug 20

Canadian GoldCamps to Acquire Majority Stake in Stealthwall West Gold Project in Québec

TIPRANKS
·
Aug 19

Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W)

TIPRANKS
·
Aug 14

CAMP4 Therapeutics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

Benzinga Earnings
·
Aug 14

Camp4 Net Loss Widens to $33.5 Million in Q2 FY26

Reuters
·
Aug 14

CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge

Reuters
·
Aug 14

Camp4 Therapeutics Corp Q2 Income from Operations USD -13.38 Million

THOMSON REUTERS
·
Aug 14